Related Experiment Videos
Frequency of lipid-lowering therapy after a coronary event in Helsinki, Finland
T E Strandberg1, H Vanhanen, M J Tikkanen
1Department of Medicine, University of Helsinki, Finland. timo.strandberg@huch.fi
The American Journal of Cardiology
|July 15, 1999
Insights
A Finnish survey reveals a significant gap in lipid-lowering medication use for coronary artery disease patients. Those diagnosed earlier were less likely to receive lipid therapy compared to recently diagnosed individuals.
Area of Science:
- Cardiology
- Public Health
- Pharmacotherapy
Background:
- Coronary artery disease (CAD) management has evolved, with lipid-lowering therapies playing a crucial role.
- Identifying treatment gaps is essential for improving patient outcomes in cardiovascular medicine.
Purpose of the Study:
- To investigate the prevalence and potential disparities in the use of lipid-lowering medications among patients with coronary artery disease in Finland.
- To assess whether the diagnosis year for coronary artery disease influences the likelihood of receiving lipid therapy.
Main Methods:
- A survey was conducted in Finland to collect data on patients with coronary artery disease.
- Patient data included diagnosis year and current lipid-lowering medication status.
Main Results:
- Survey results indicate a notable treatment gap concerning lipid-lowering medications.
- Patients diagnosed with coronary artery disease before 1995 showed a lower likelihood of being on lipid therapy compared to those diagnosed more recently.
Conclusions:
- The findings suggest a potential underutilization or delayed initiation of lipid-lowering therapies in a segment of the coronary artery disease patient population.
- Further research and clinical interventions may be needed to address this identified treatment gap and optimize cardiovascular risk management.
Abstract:
The results from a survey in Finland suggest an important treatment gap of lipid-lowering medications. Patients whose coronary artery disease was diagnosed before 1995 were less likely to be on lipid therapy than patients with a more recent diagnosis.